U-Protein Express ™

U-Protein Express BV is a dedicated CRO that has many years experience in recombinant protein production. At U-Protein Express BV fully post-translational modified mammalian recombinant proteins or recombinant antibodies are produced via its r-PEx transient expression platform (patent applications pending). The r-PEx expression platform is based on Human Embryonic Kidney cells (HEK293E) and yields 1-100 mg amount of recombinant protein in 4-6 weeks.

If you need more information please send us an email and we will contact you as soon as possible.

January 27^th, 2012:

U-Protein Express BV, Crossbeta Biosciences and Good Biomarker Sciences join forces to develop Alzheimer’s disease biomarker with a grant from IPC-BioFarmind.

December 1^st, 2011:

U-Protein Express BV acquires patent rights for protein sequencing by mass spectroscopy from the Utrecht University, The Netherlands. Download the press release.

May 24-26 2011:

Visit us at the Recombinant Antibodies Conference 2011 in Barcelona.

April 3-7 2011:

Read our advertisement for Lys-N at the Proteomic Forum, Berlin, page 34.

October 5-7 2010:

Visit us at Biotechnica, Hannover.

August 2010:

First publication for the use of recombinant Lys-N in Biochemistry.

June 7^th, 2010:

Prof. Dr. Piet Gros receives Spinoza Prize.

May 29^th, 2010:

ArGEN-X licenses r-PEx technology. Press release May 2010.

October 20^th, 2009:

Visit us at Life Sciences Momentum 2009.

September 2009:

Launch of recombinant Lys-N for protein sequencing by Mass Spectroscopy. Download the flyer here.

January 2009:

U-Protein Express BV joins CTMM-predicct.

December 2008:

FND-Innovation project approved.

April 2008:

U-Protein Express BV sponsors Bijvoet 20th annual symposium.

November 2007:

FND-Feasibility approved.

November 2007:

Transition of ABC expertise center "Expression Center" to U-Protein Express BV (publication in Dutch).